Patents by Inventor Kathleen L. Coelingh
Kathleen L. Coelingh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120294890Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: December 19, 2011Publication date: November 22, 2012Applicant: Medlmmune, LLCInventors: Aurelia Haller, Kathleen L. Coelingh
-
Publication number: 20100239585Abstract: The present invention provides antibodies that immunospecifically bind to a polypeptide of a mammalian metapneumovirus, compositions comprising said antibodies, and methods for producing such antibodies. In particular, the invention provides monoclonal antibodies that immunospecifically bind to the F protein of human metapneumovirus and that neutralize human metapneumovirus. The invention also provides antibodies that cross-react with both the F protein of a mammalian metapneumovirus and the F protein of a mammalian respiratory syncytial virus and that neutralize both viruses. Further, the invention provides recombinant antibodies, such as humanized antibodies, against mammalian metapneumovirus, and methods for producing such recombinant antibodies. The invention further provides methods for treating, managing, ameliorating symptoms of and/or preventing infections with mammalian metapneumovirus, such as human metapneumovirus.Type: ApplicationFiled: September 14, 2009Publication date: September 23, 2010Applicant: Medimmune, LLCInventors: Nancy Ulbrandt, JoAnn Suzich, Kathleen L. Coelingh
-
Publication number: 20100119547Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: January 27, 2010Publication date: May 13, 2010Applicant: MedImmune, LLCInventors: Aurelia Haller, Kathleen L. Coelingh
-
Publication number: 20090004722Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: January 16, 2008Publication date: January 1, 2009Applicant: Medlmmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Publication number: 20080160018Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 ? as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: November 20, 2006Publication date: July 3, 2008Applicant: PDL BioPharma, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: 7341729Abstract: The present invention relates to recombinant bovine para influenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: September 3, 2004Date of Patent: March 11, 2008Assignee: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 7238481Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: April 14, 2004Date of Patent: July 3, 2007Assignee: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 6843996Abstract: Recombinant PB2 variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and methods for the prophylactic treatment of influenza in humans.Type: GrantFiled: December 1, 1999Date of Patent: January 18, 2005Assignee: Medimmune Vaccines, Inc.Inventors: Neil T. Parkin, Kathleen L. Coelingh
-
Patent number: 6811784Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: September 20, 2002Date of Patent: November 2, 2004Assignee: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Publication number: 20040208895Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: April 14, 2004Publication date: October 21, 2004Applicant: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 6764685Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: March 21, 2000Date of Patent: July 20, 2004Assignee: MedImmune Vaccines, Inc.Inventors: Auriela Haller, Kathleen L. Coelingh
-
Publication number: 20040058414Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: May 30, 2003Publication date: March 25, 2004Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20040049014Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: March 11, 2004Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030229208Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: December 11, 2003Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030095987Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: September 20, 2002Publication date: May 22, 2003Applicant: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 5693762Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: December 2, 1997Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: 5690937Abstract: Recombinant PB2 variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and methods for the prophylactic treatment of influenza in humans.Type: GrantFiled: June 5, 1995Date of Patent: November 25, 1997Assignee: AvironInventors: Neil T. Parkin, Kathleen L. Coelingh